Evidence has demonstrated that PHGDH has additional enzymatic activity by converting NADH-dependent reduction of α-KG to the oncometabolite D-2-hydroxyglutarate (D-2HG) in breast cancer 49, 50. This evidence concerns the gene PHGDH and breast carcinoma.